83 related articles for article (PubMed ID: 19951305)
1. Pathogen inactivation/reduction of platelet concentrates: turning theory into practice.
Gathof BS; Tauszig ME; Picker SM
ISBT Sci Ser; 2010 Jul; 5(n1):114-119. PubMed ID: 32328165
[No Abstract] [Full Text] [Related]
2. The impact of policies to restrict the use of plasma containing products and apheresis platelets from female donors to mitigate transfusion related acute lung injury (TRALI) in Brazil.
Blatyta PF; Custer B; Liu J; Mendrone-Junior A; Wright DJ; Leão SC; Lopes MI; Carneiro-Proietti AB; Sabino EC; de Almeida-Neto C;
Transfus Apher Sci; 2013 Feb; 48(1):15-20. PubMed ID: 22985535
[TBL] [Abstract][Full Text] [Related]
3. Introducing Pathogen Reduction Technology in Poland: A Cost-Utility Analysis.
Agapova M; Lachert E; Brojer E; Letowska M; Grabarczyk P; Custer B
Transfus Med Hemother; 2015 May; 42(3):158-65. PubMed ID: 26195929
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of bacterial safety approaches of platelet blood concentrates: bacterial screening and pathogen reduction.
Rezvany MR; Moradi Hasan-Abad A; Sobhani-Nasab A; Esmaili MA
Front Med (Lausanne); 2024; 11():1325602. PubMed ID: 38651065
[TBL] [Abstract][Full Text] [Related]
5. Update on transfusion-related acute lung injury: an overview of its pathogenesis and management.
Yu Y; Lian Z
Front Immunol; 2023; 14():1175387. PubMed ID: 37251400
[TBL] [Abstract][Full Text] [Related]
6. Aged versus fresh autologous platelet transfusion in a two-hit healthy volunteer model of transfusion-related acute lung injury.
van Baarle FLF; de Bruin S; Bulle EB; van Mourik N; Lim EHT; Tuip-de Boer AM; Bongers A; de Wissel MB; van Bruggen R; de Korte D; Vermeulen C; Tan KW; Jonkers RE; Bonta PI; Lutter R; Dekker T; Dierdorp BS; Peters AL; Biemond BJ; Vlaar APJ
Transfusion; 2022 Dec; 62(12):2490-2501. PubMed ID: 36300793
[TBL] [Abstract][Full Text] [Related]
7. Supernatants and lipids from stored red blood cells activate pulmonary microvascular endothelium through the BLT2 receptor and protein kinase C activation.
Silliman CC; Kelher MR; Khan SY; West FB; McLaughlin NJD; Elzi DJ; England K; Bjornsen J; Kuldanek SA; Banerjee A
Transfusion; 2017 Nov; 57(11):2690-2700. PubMed ID: 28880373
[TBL] [Abstract][Full Text] [Related]
8. The accumulation of lipids and proteins during red blood cell storage: the roles of leucoreduction and experimental filtration.
Silliman CC; Burke T; Kelher MR
Blood Transfus; 2017 Mar; 15(2):131-136. PubMed ID: 28263170
[TBL] [Abstract][Full Text] [Related]
9. LysoPCs induce Hck- and PKCδ-mediated activation of PKCγ causing p47phox phosphorylation and membrane translocation in neutrophils.
Kelher MR; McLaughlin NJ; Banerjee A; Elzi DJ; Gamboni F; Khan SY; Meng X; Mitra S; Silliman CC
J Leukoc Biol; 2017 Jan; 101(1):261-273. PubMed ID: 27531930
[TBL] [Abstract][Full Text] [Related]
10. Health Technology Assessment of pathogen reduction technologies applied to plasma for clinical use.
Cicchetti A; Berrino A; Casini M; Codella P; Facco G; Fiore A; Marano G; Marchetti M; Midolo E; Minacori R; Refolo P; Romano F; Ruggeri M; Sacchini D; Spagnolo AG; Urbina I; Vaglio S; Grazzini G; Liumbruno GM
Blood Transfus; 2016 Jul; 14(4):287-386. PubMed ID: 27403740
[TBL] [Abstract][Full Text] [Related]
11. Role of Riboflavin- and UV Light-Treated Plasma in Prevention of Transfusion-Related Acute Lung Injury.
Jimenez-Marco T; Ruiz-Alderton D; Bautista-Gili AM; Girona-Llobera E
Transfus Med Hemother; 2014 Jun; 41(3):172-5. PubMed ID: 25053929
[TBL] [Abstract][Full Text] [Related]
12. Biological response modifiers in photochemically pathogen-reduced versus untreated apheresis platelet concentrates.
Vetlesen A; Mirlashari MR; Akkök CA; Kelher MR; Khan SY; Silliman CC; Kjeldsen-Kragh J
Transfusion; 2013 Jan; 53(1):147-55. PubMed ID: 22563732
[TBL] [Abstract][Full Text] [Related]
13. Age of blood and recipient factors determine the severity of transfusion-related acute lung injury (TRALI).
Tung JP; Fraser JF; Nataatmadja M; Colebourne KI; Barnett AG; Glenister KM; Zhou AY; Wood P; Silliman CC; Fung YL
Crit Care; 2012 Feb; 16(1):R19. PubMed ID: 22297161
[TBL] [Abstract][Full Text] [Related]
14. Pathogen Reduction Technology Treatment of Platelets, Plasma and Whole Blood Using Riboflavin and UV Light.
Marschner S; Goodrich R
Transfus Med Hemother; 2011; 38(1):8-18. PubMed ID: 21779202
[TBL] [Abstract][Full Text] [Related]
15. Identification of lipids that accumulate during the routine storage of prestorage leukoreduced red blood cells and cause acute lung injury.
Silliman CC; Moore EE; Kelher MR; Khan SY; Gellar L; Elzi DJ
Transfusion; 2011 Dec; 51(12):2549-54. PubMed ID: 21615744
[TBL] [Abstract][Full Text] [Related]
16. Real-Time Live Confocal Fluorescence Microscopy as a New Tool for Assessing Platelet Vitality.
Hermann M; Nussbaumer O; Knöfler R; Hengster P; Nussbaumer W; Streif W
Transfus Med Hemother; 2010; 37(5):299-305. PubMed ID: 21113254
[TBL] [Abstract][Full Text] [Related]
17. Mirasol Pathogen Reduction Technology treatment does not affect acute lung injury in a two-event in vivo model caused by stored blood components.
Silliman CC; Khan SY; Ball JB; Kelher MR; Marschner S
Vox Sang; 2010 May; 98(4):525-30. PubMed ID: 19951305
[TBL] [Abstract][Full Text] [Related]
18. Generation of neutrophil priming activity by cell-containing blood components treated with pathogen reduction technology and stored in platelet additive solutions.
Ambruso DR; Thurman G; Tran K; Marschner S; Gathof B; Janetzko K; Goodrich RP
Transfusion; 2011 Jun; 51(6):1220-7. PubMed ID: 21155831
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
